


Applicant: de Groot, et al.
Serial No: Unassigned
Our Docket: 294-120 PCT/US
Page 4

result of the present Amendment, Claims 1-21 remain in the application for purpose of prosecution.

As a result of this Amendment no additional fees should be assessed as a result of filing multiple dependent claims. Therefore, since new matter has not been introduced as a result of this Amendment, entry hereof and examination and favorable consideration are respectfully requested. Any questions regarding this matter should be directed to the undersigned.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Ronald J. Baron', is written over a horizontal line.

Ronald J. Baron
Registration No: 29,281
Attorney for Applicant

HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791
(516) 822-3550
RJB/jmn

Applicant: de Groot, et al.
Serial No: Unassigned
Our Docket: 294-120 PCT/US
Page 5

VERSION OF AMENDMENT WITH MARKS
TO SHOW CHANGES MADE

IN THE SPECIFICATION:

On page 1, before line 1, after the title, please insert the following:

This application is the U.S. National Phase of International Application
Number PCT/NL00/00569, filed August 14, 2000, which is incorporated herein by reference.

BACKGROUND OF THE INVENTION

On page 2, after line 22, insert the following:

SUMMARY OF THE INVENTION

On page 3, after line 13, insert the following:

DETAILED DESCRIPTION OF THE PREFERRED
EMBODIMENTS IN THE CLAIMS:

IN THE CLAIMS:

Please amend Claims 3 - 8, 14, and 15, to read as follows:

3. (Amended) The vaccine or medical preparation according to claim 1 [or 2],
further comprising a suitable adjuvant or carrier.

Applicant: de Groot, et al.
Serial No: Unassigned
Our Docket: 294-120 PCT/US
Page 6

4. (Amended) The vaccine or medical preparation according to claim 1 [anyone of the claims 1-3], wherein said protein comprises an amino acid sequence as shown in fig. 1B.

5. (Amended) The vaccine or medical according to claim 1 [anyone of the claims 1-4], wherein said protein is the protein maturation protein from *S. pneumoniae* Ft231 or EF3296.

6. (Amended) The vaccine or medical preparation according to claim 1 [anyone of the claims 1-5], wherein said fragment comprises an anchoring fragment, an antigenic fragment or a functional equivalent thereof for a functional equivalent of a receptor binding site or an antibody binding site.

7. (Amended) The vaccine or medical preparation according to claim 1 [anyone of the claims 1-6], wherein said protein or said fragment comprises a purified, partly purified, recombinant or synthetic protein or fragment thereof.

8. (Amended) The vaccine or medical preparation according to claim 1
[anyone of the claims 1-7], wherein said fragment comprises at least 8 amino acids.

14. (Amended) Method of treatment of *S. pneumoniae* infection comprising administering a vaccine according to claim 1 [claims 1-8].

Applicant: de Groot, et al.
Serial No: Unassigned
Our Docket: 294-120 PCT/US
Page 7

15. (Amended) Method for the vaccination of a mammal against an infection of *S. pneumoniae* comprising administering a suitable dose of a vaccine according to claim 1 [anyone of the claims 1-8].